Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
| Status: | Archived |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2008 |
| End Date: | December 2012 |
Modulating Effects of Lisinopril on Sildenafil Activity in PAH (MELISSA)
Patients with pulmonary arterial hypertension(PAH) suffer from chronic shortness of breath,
and have impaired survival related to progressive right ventricular failure. Abnormal
vasoreactivity to nitric oxide(NO) plays a role in the pathophysiology of PAH.
Phosphodiesterase Type 5 Inhibitor (PDE5 inhibitors) sildenafil have been shown to be
beneficial in PAH, but extent of benefit is variable.
The broad aim of this investigation is to determine whether the modulating effect of
angiotensin converting enzyme inhibition on vascular smooth muscle responsiveness to the
nitric oxide pathway that we have observed in an animal model of Congestive Heart
Failure(CHF) can be exploited in humans with PAH. Furthermore, we have identified a group
of genes TAO kinase I, IL-10, Rho kinase, Raf1, bile acid coenzyme A and Fmr1 that are
modulated by long-acting angiotensin-converting enzyme inhibitor (ACEI) in our animal model,
and therefore may also be modulated by ACEI in patients with PAH
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
